321 related articles for article (PubMed ID: 21254946)
1. Medical approaches to preservation of fertility in female cancer patients.
Del Mastro L; Giraudi S; Levaggi A; Pronzato P
Expert Opin Pharmacother; 2011 Feb; 12(3):387-96. PubMed ID: 21254946
[TBL] [Abstract][Full Text] [Related]
2. Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists.
Hickman LC; Valentine LN; Falcone T
Am J Obstet Gynecol; 2016 Oct; 215(4):415-22. PubMed ID: 27422055
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
4. [Premature ovarian failure after chemotherapy for breast cancer].
Mathelin C; Brettes JP; Diemunsch P
Bull Cancer; 2008 Apr; 95(4):403-12. PubMed ID: 18495569
[TBL] [Abstract][Full Text] [Related]
5. Fertility preservation options for women with malignancies.
Marhhom E; Cohen I
Obstet Gynecol Surv; 2007 Jan; 62(1):58-72. PubMed ID: 17176489
[TBL] [Abstract][Full Text] [Related]
6. Present and future fertility preservation strategies for female cancer patients.
Georgescu ES; Goldberg JM; du Plessis SS; Agarwal A
Obstet Gynecol Surv; 2008 Nov; 63(11):725-32. PubMed ID: 18928577
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients.
Conte B; Del Mastro L
Minerva Ginecol; 2017 Aug; 69(4):350-356. PubMed ID: 28398024
[TBL] [Abstract][Full Text] [Related]
8. Strategies for fertility preservation in young early breast cancer patients.
Tomasi-Cont N; Lambertini M; Hulsbosch S; Peccatori AF; Amant F
Breast; 2014 Oct; 23(5):503-10. PubMed ID: 24934638
[TBL] [Abstract][Full Text] [Related]
9. Protection of ovarian function by GnRH agonists during chemotherapy: a meta-analysis.
Sun X; Dongol S; Jiang J; Kong B
Int J Oncol; 2014 Apr; 44(4):1335-40. PubMed ID: 24535045
[TBL] [Abstract][Full Text] [Related]
10. Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity.
Garrido-Oyarzún MF; Castelo-Branco C
Climacteric; 2016 Dec; 19(6):522-525. PubMed ID: 27644002
[TBL] [Abstract][Full Text] [Related]
11. Use of hormonal protection for chemotherapy-induced gonadotoxicity.
Kim SS; Lee JR; Jee BC; Suh CS; Kim SH; Ting A; Petroff B
Clin Obstet Gynecol; 2010 Dec; 53(4):740-52. PubMed ID: 21048441
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
[TBL] [Abstract][Full Text] [Related]
13. The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies.
Lei YY; Yeo W
Expert Opin Drug Saf; 2021 Oct; 20(10):1163-1175. PubMed ID: 33951990
[No Abstract] [Full Text] [Related]
14. [Statement: cancer treatments and ovarian reserve].
Basille C; Torre A; Grynberg M; Gallot V; Frydman R; Fanchin R
J Gynecol Obstet Biol Reprod (Paris); 2010 Oct; 39(6):433-43. PubMed ID: 20674192
[TBL] [Abstract][Full Text] [Related]
15. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.
Blumenfeld Z; Evron A
Expert Opin Pharmacother; 2015 May; 16(7):1009-20. PubMed ID: 25826240
[TBL] [Abstract][Full Text] [Related]
16. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
[TBL] [Abstract][Full Text] [Related]
17. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury.
Oktay K; Sönmezer M; Oktem O; Fox K; Emons G; Bang H
Oncologist; 2007 Sep; 12(9):1055-66. PubMed ID: 17914075
[TBL] [Abstract][Full Text] [Related]
18. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application.
Lambertini M; Horicks F; Del Mastro L; Partridge AH; Demeestere I
Cancer Treat Rev; 2019 Jan; 72():65-77. PubMed ID: 30530271
[TBL] [Abstract][Full Text] [Related]
19. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
Whitehead J; Toledo MG; Stern CJ
Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
[TBL] [Abstract][Full Text] [Related]
20. Fertility preservation in women with CNS tumors.
Tosoni A; Balestrini D; Brandes AA
Expert Rev Anticancer Ther; 2017 May; 17(5):439-445. PubMed ID: 28395560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
